Dr. Rohan Kalyan Rej completed his Ph.D. in Organic Chemistry from the Indian Institute of Technology Kharagpur, India, in 2015, followed by a postdoctoral fellowship at Purdue University, USA (2015-2016) and University of Michigan, USA (2016-2020). At present, Dr. Rej works as a research track faculty at the University of Michigan, USA. His research interests lie in the design, synthesis, discovery, and development of novel anticancer drugs. A number of peer-reviewed publications bear his name, and he is the inventor of several US patents. Dr. Rej has notably spearheaded the team that advanced EEDi-5273 (APG-5918, EED inhibitor) to phase 1 clinical development which is a significant progress in the treatment of Advanced Solid Tumors (NCT05415098) or Lymphomas and Sickle Cell Disease (NCT05773586). Dr. Rej has also played a key role in the development of several other drugs currently in the advanced preclinical stage. Notably among them, PVTX-321 (Exceptionally Potent and Orally Efficacious estrogen receptor heterobifunctional degrader) and PVTX-405 (IKZF2 Selective Molecular Glue Degrader) which have reached the development candidate nomination stage.

Joyeeta Roy was born in Kolkata, India. She received her Ph.D. from Indian Institute of Technology, Kharagpur, India in total synthesis of carbazole based natural products. She competed her a post-doctoral fellowship in Louisiana State University and University of Michigan, USA. She is currently the Research Laboratory Specialist Senior in College of Pharmacy, University of Michigan, USA. Her current research involves design and synthesis of novel small molecules and PROTACs as cancer therapeutics. She has published 15 research articles and is the inventor of 2 US patents.

Dr. Srinivasa Rao Allu, completed his Ph.D. in Organic Chemistry at Chongqing University, Chongqing, China in 2018. Dr. Allu has an impressive educational and research journey, spanning various countries and institutions. Like, a postdoctoral research associate at Purdue University, USA (2018-2021), Helmholtz Center for Infection Research, Braunschweig, Germany (2021-2023), and the University of Michigan, USA (2023-Present). His research interests are the total synthesis of natural products and their structure-activity relationship (SAR) studies, design, synthesis, discovery, and development of novel anticancer and anti-tuberculosis drugs, and synthetic methodology. Dr. Allu has several peer-reviewed publications in his name. Dr. Allu has diverse and international research experience, focusing on both organic chemistry and drug discovery. His work in the synthesis of natural products and the development of novel drugs for cancer and tuberculosis indicates a commitment to advancing scientific knowledge and addressing critical health challenges.